| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
IM Cannabis Corp. Common Shares$0.12
0 (-1.86%)
0Pipeline Score NOT_PHARMA · Pre-Clinical
Market Cap
1.12 M
EPS
-1.48
P/E Ratio
-
Value Trade
111.36 K
7.69 %
Week
-19.55 %
1 Month
-48.89 %
3 Month
-89.16 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
526.98 K
52 Week Range
0.10 - 3.13
% held by Insiders
35.15 %
% held by Institutions
0.12 %
Enterprise Value
11.78 M
Total Shares
9.02 M
Short %
10.7 %
Float Shares
4.80 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for IM Cannabis Corp. Common Shares
211Total events
0Upcoming
57Tier-1 (high impact)
2021 – 2026Coverage
Event history 2
TBD
●Management ChangeCorporate
Subscribe to view catalyst details
TBD
◆Debt Royalty FinancingCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
0
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 2%
Micro Cap (rank 906 of 923)
Percentile RankClinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IMCC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IMCC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-IMCC
Aug 7, 2026▼ -1.9%today
IM Cannabis Raises US$250,000 of Gross Proceeds in Convertible Note Financing
IM Cannabis Corp. has successfully closed a US$250,000 convertible note financing with an institutional investor. The financing includes an 8% interest note convertible into common shares at a set price or a percentage of market value. The company plans to use the proceeds for general corporate purposes while managing risks associated with regulatory compliance and market competition.
Read more →-IMCC
Jul 27, 2026IM Cannabis Provides Corporate Update
IM Cannabis Corp. has announced the resignation of Mr. Alon Dayan from its board of directors for personal reasons. The company expressed appreciation for his contributions during his tenure. IM Cannabis continues to focus on expanding its medical cannabis operations in Israel and Germany, while exploring new technology-driven opportunities.
Read more →-IMCC
Jun 18, 2026▼ -16.5%on this news
IM Cannabis Corp. Enters into Letter of Intent to Sell its European Activities, Expects to Significantly Reduce Debt by CAD$10.5 million
IM Cannabis Corp. has entered a non-binding letter of intent to sell its European operations to Slil.com Holding Ltd., which will significantly reduce the company's debt by CAD$10.5 million. The transaction allows IMC to concentrate on its Israeli market while pursuing new investment opportunities. The deal is subject to further negotiations and regulatory approvals.
Read more →-IMCC
Jun 9, 2026▼ -14.5%on this news
IM Cannabis Announces Form F-3 Resale Registration Statement Filing
IM Cannabis Corp. has announced the filing of a resale registration statement on Form F-3 with the SEC for 17,276,931 common shares. This registration includes shares from several convertible promissory notes, emphasizing the company's focus on managing its financial operations. While the statement has potential benefits for liquidity, it has not yet been made effective by the SEC, introducing an element of uncertainty. The company continues to operate in the medical cannabis market primarily in Israel and Germany.
Read more →-IMCC
Jun 3, 2026IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing
IM Cannabis Corp. has finalized a convertible note financing deal, raising US$225,000 from an institutional investor. The financing terms include an interest rate of 8% per annum, potentially increasing to 14% upon an event of default. The proceeds are aimed at funding general corporate activities, helping the company bolster its operations in the medical cannabis sector. Furthermore, the company will issue warrants as part of this financing deal, indicating an effort to provide future growth and investor confidence.
Read more →-IMCC
May 13, 2026IM Cannabis Corp. Announces First Quarter 2026 Financial ResultsUSA - EnglishIsrael - English
IM Cannabis Corp. announced its financial results for Q1 2026, reporting revenues of $8.7 million but a net loss of $2.5 million. The company has made strides in cost optimization, reducing administrative expenses by 22% year-over-year. Management is focused on operational efficiencies and exploring strategic growth opportunities despite facing inherent risks in the cannabis industry.
Read more →-IMCC
May 7, 2026IM Cannabis Raised US$550,000 of Gross Proceeds in Convertible Note Financings
IM Cannabis Corp. has successfully closed a US$300,000 convertible note financing, adding to a total of US$550,000 raised in recent financings. The funds will be utilized for general corporate purposes. The company operates in Israel and Germany, focusing on medical cannabis distribution and retail. However, it faces regulatory and market challenges that could impact its future growth.
Read more →-IMCC
Apr 10, 2026IMC Announces Receipt of Nasdaq Minimum Bid Price Notification
IM Cannabis Corp. (IMC) has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per share. The company has 180 days to regain compliance, during which its shares will continue to trade. If compliance is not achieved, IMC may qualify for an additional compliance period but risks delisting if it fails to meet requirements.
Read more →-IMCC
Mar 31, 2026▼ -9.3%on this news· ran to -25% by day 1
IM Cannabis Reports 2025 Results: Revenue of C$54.7 Million with Over 134% Growth in Germany and Positive Operating Cash FlowUSA - EnglishIsrael - English
IM Cannabis Corp. reported a significant operational turnaround in 2025, achieving positive cash flow of C$4.7 million and over 134% revenue growth in Germany. The company is diversifying its business by planning to acquire a 51% stake in Black Axe Technologies, which specializes in defense technology. Despite these achievements, IMC faces regulatory and geopolitical risks that could impact its future operations.
Read more →-IMCC
Mar 17, 2026▼ -19.4%on this news
IMC Announces a Strategic Entry to the Cyber Drone Interception and Satellite Intelligence Markets by Signing a Non-Binding Agreement to Acquire 51% of Blackaxe TechnologiesUSA - EnglishIsrael - English
IM Cannabis Corp. (IMC) has announced a non-binding agreement to acquire 51% of Blackaxe Technologies, a Polish firm specializing in defense and intelligence solutions. This move marks IMC's strategic entry into the defense sector, addressing the rising demand for satellite intelligence and counter-drone technologies amid global geopolitical tensions. The transaction is contingent upon due diligence and regulatory approvals.
Read more →-IMCC
Jan 26, 2026IM Cannabis Raises US$2,171,660.40 in Note Purchase AgreementsUSA - EnglishIsrael - English
IM Cannabis Corp. has raised US$2,171,660.40 through two note purchase agreements to address liquidity needs. The financing includes two notes with varying principal amounts and interest rates, both convertible into common shares. A portion of the proceeds will be used to repay creditors, enhancing the company's financial position while also funding operational initiatives.
Read more →-IMCC
Jan 5, 2026IM Cannabis Announces the Appointment of Mr. Alon Dayan to its Board of DirectorsUSA - EnglishIsrael - English
IM Cannabis Corp. has appointed Mr. Alon Dayan to its board of directors, effective December 31, 2025. Mr. Dayan, currently the CEO of KeepZone AI Inc., has over 15 years of experience in the homeland security technology sector. His background includes founding and scaling companies focused on secure communications and international business development.
Read more →-IMCC
Dec 30, 2025IM Cannabis Explores U.S. Market Entry Following President Trump's Executive Order on Increasing Medical Marijuana and Cannabidiol ResearchUSA - EnglishIsrael - English
IM Cannabis Corp. is evaluating opportunities to enter the U.S. cannabis market following President Trump's executive order aimed at rescheduling marijuana. The company has engaged SSC Advisors to assist in this strategic initiative and to explore potential divestitures of its operations in Germany and Israel. IMC aims to leverage its experience in international medical cannabis to capitalize on new market opportunities.
Read more →-IMCC
Dec 12, 2025▲ +12.6%on this news
IM Cannabis Appoints Asi Levi as Chief Financial Officer
IM Cannabis Corp. has appointed Asi Levi as its new Chief Financial Officer, effective immediately, replacing Uri Birenberg. Levi comes with over 15 years of financial expertise, having held CFO positions at various companies and overseen significant financial operations. This leadership change is part of IMC's strategy to strengthen its financial management as it continues to focus on growth in medical cannabis markets in Israel and Germany.
Read more →-IMCC
Nov 13, 2025▼ -9%on this news
IM Cannabis Reports Third Quarter 2025 Financial ResultsUSA - EnglishIsrael - English
IM Cannabis Corp. reported its financial results for Q3 2025, highlighting a transition year impacted by potential regulatory changes in Germany. The company recorded a non-cash impairment and is assessing new business opportunities for growth. Concerns about its ability to continue as a going concern were also noted in the financial statements.
Read more →-IMCC
Nov 6, 2025IM Cannabis to Report third Quarter 2025 Financial Results on Thursday, November 13th at 9:00am ETUSA - EnglishIsrael - English
IM Cannabis Corp. will announce its third quarter 2025 financial results on November 13, 2025. The report will cover operational and financial performance for the period ending September 30, 2025. IMC operates in Israel and Germany, focusing on premium medical cannabis products and sustainable growth. The company aims to enhance its market presence through a data-driven approach.
Read more →-IMCC
Oct 23, 2025IM Cannabis Signs Non-Binding Term Sheet to Acquire 60% Stake in Innovative Quantum Computing Bio Data Company for Up to $54 MillionUSA - EnglishIsrael - English
IM Cannabis Corp. has signed a non-binding term sheet to acquire a 60% stake in a quantum computing bio data company for up to $54 million. This strategic move aims to enhance the company's growth and shareholder value by leveraging innovative technologies in biological data processing. However, the deal is contingent on due diligence and regulatory approvals, with no assurance of completion.
Read more →-IMCC
Sep 16, 2025IM Cannabis Announces Board Changes and Strategic Decision to Identify Additional Business OpportunitiesUSA - EnglishIsrael - English
IM Cannabis Corp. has announced changes to its Board of Directors, with the resignation of Shmulik Arbel and Brian Schinderle. New members Asaf Yitzhaik and Eli Zamir have been appointed to fill these vacancies. The company is also exploring additional business opportunities to enhance growth and shareholder value.
Read more →-IMCC
Sep 5, 2025IM Cannabis Regains Compliance with Nasdaq Stockholders' Equity Listing RequirementUSA - EnglishIsrael - English
IM Cannabis Corp. has announced that it has regained compliance with Nasdaq's stockholders' equity listing requirement, allowing its common stock to continue trading on the Nasdaq Capital Market. The company operates in Israel and Germany, providing medical cannabis products while adhering to strict regulatory standards. Despite this positive development, IM Cannabis faces various risks, including regulatory compliance and market competition.
Read more →-IMCC
Aug 13, 2025IM Cannabis Announces Warrant Amendments and Form F-3 Resale Registration Statement FilingUSA - EnglishIsrael - English
IM Cannabis Corp. has announced amendments to its November 2024 Warrants, reducing the exercise price from C$4.32 to C$3.43 and extending the expiration date to July 31, 2030. Additionally, the company filed a Form F-3 Resale Registration Statement with the SEC, registering nearly 5 million common shares. The transaction involved related party participation, which has raised some regulatory considerations.
Read more →-IMCC
Aug 12, 2025▼ -11.3%on this newsshared move
IM Cannabis Reports Second Quarter 2025 Financial Results
IM Cannabis Corp. (IMCC) reported its financial results for Q2 2025, highlighting a significant increase in gross profit and margin despite a decrease in revenue. The company experienced a 14% decline in revenue due to challenges related to the ongoing conflict in Israel and supply chain issues. However, IMC achieved a gross profit of $3.4 million, a 306% increase from the previous year, alongside a return to EBITDA profitability. Management is optimistic about recovery and sustainable growth moving forward.
Read more →-IMCC
Aug 4, 2025IM Cannabis to Report Second Quarter 2025 Financial Results on Tuesday, August 12th at 9:00am ET
IM Cannabis Corp. (NASDAQ: IMCC) announced that it will report its financial results for the second quarter of 2025 on August 12, 2025, prior to market opening. The company continues to operate in the medical cannabis sectors of Israel and Germany, focusing on premium cannabis products. IMC aims for sustainable growth while maintaining compliance with regulatory standards and harnessing a unique global supply chain.
Read more →-IMCC
Jul 31, 2025IM Cannabis Closes Private Placement for Gross Proceeds of Approximately US$4.1 Million
IM Cannabis Corp. has successfully completed a private placement of 2,050,000 units, raising approximately US$4.1 million. The funds will be used for working capital and to repay existing debts. Each unit includes common shares and warrants, with specific terms outlined for their exercise. The offering is exempt from certain registration requirements under U.S. securities law, allowing for a limited timeframe for resale registration.
Read more →-IMCC
Jul 11, 2025▼ -15.4%on this news
IM CANNABIS ANNOUNCES FILING OF SHELF REGISTRATION STATEMENT ON FORM F-3
IM Cannabis Corp. has announced the filing of a shelf registration statement on Form F-3 with the SEC, enabling it to offer and sell up to $50 million in common shares and other securities. This allows flexibility in financing options to meet capital needs while complying with market conditions. The company emphasizes its commitment to responsible growth and operations in the medical cannabis sectors of Israel and Germany. The registration does not guarantee a specific amount of securities will be sold, as it is subject to market demand and timing.
Read more →-IMCC
Jul 9, 2025▲ +5.5%on this newsshared move
IM Cannabis Announces the Signing of a Loan Agreement and Appointment of Oz Adler to Board of Directors
IM Cannabis Corp. has announced the appointment of Oz Adler to its board of directors alongside a loan agreement with L.I.A. Pure Capital Ltd., providing the Company with USD 1 million initially, with the possibility of an additional USD 1 million. Adler's background in finance and compliance is expected to support IMC's growth strategy. The loan has specific repayment terms and conditions, including a high interest rate and acceleration rights for the lender. The Company is also aiming to raise at least USD 3 million within 60 days to enhance its capital position.
Read more →-IMCC
Jul 1, 2025▲ +8.9%on this news· ran to +33% by day 3
IM Cannabis Provides Corporate Updates
IM Cannabis Corp. announced updates regarding its compliance status with Nasdaq listing requirements. The company received a deficiency letter indicating noncompliance with certain stockholders' equity rules, prompting it to submit a Compliance Plan. Nasdaq has granted the company an extension until October 6, 2025, to regain compliance. Despite current noncompliance, IMC's shares will continue to trade on Nasdaq while the company explores necessary measures to meet the requirements.
Read more →-IMCC
May 28, 2025▲ +44.9%on this news· ran to +167% by day 1
IM Cannabis Announces Plans to Voluntarily Delist from the Canadian Securities Exchange
IM Cannabis Corp. has announced its application for a voluntary delisting from the Canadian Securities Exchange (CSE), effective June 2, 2025, while continuing to trade on NASDAQ. The decision stems from the company’s assessment that the CSE listing incurs unnecessary costs and administrative burdens without justifying the trading volume. IM Cannabis aims to create a centralized marketplace on NASDAQ, which they believe will enhance shareholder value and simplify operations. The company expressed gratitude to the CSE for its initial support in accessing public markets.
Read more →-IMCC
May 15, 2025▲ +7.4%on this news
IM Cannabis Reports First Quarter Financial Results
IM Cannabis Corp. reported its financial results for Q1 2025, revealing a net profit of $0.2 million compared to a net loss of $6 million in Q1 2024. The company achieved a 94% increase in gross profit year-over-year, demonstrating significant operational improvements and a reduction in operating expenses. However, the revenue decline in Israel raises some concerns, although overall revenue in Q1 2025 reached $12.5 million, up from $12.1 million in Q1 2024. IMC also plans a private placement of secured convertible debentures to support future growth.
Read more →-IMCC
May 7, 2025▼ -5.7%on this news
IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction
IM Cannabis Corp. has announced the filing of a management information circular for its upcoming annual general and special meeting set for May 23, 2025. The circular includes details on the proposed Focus Transaction, which is valued at approximately NIS 3.1 million based on future cash flows. The Company aims to settle the Focus Purchase Price through the issuance of Common Shares, pending shareholder approval. The announcement highlights the Company's commitment to transparency and compliance as it navigates its operations in the cannabis market.
Read more →-IMCC
May 6, 2025▲ +11.4%on this newsshared move
IM Cannabis to Report First Quarter 2025 Financial Results on Thursday, May 15th at 9:00am ET
IM Cannabis Corp. will report its financial results for the first quarter of 2025 on May 15, 2025. The company, which operates in Israel and Germany, will conduct a web conference at 9:00 AM ET to discuss its performance and answer investor questions. This event emphasizes IMC's commitment to transparency and investor relations as they navigate the medical cannabis market.
Read more →-IMCC
Mar 31, 2025▼ -17.9%on this news
IM Cannabis Reports Fourth Quarter and Full Year 2024 Financial Results
IM Cannabis Corp. reported its fourth quarter and full year 2024 financial results, showcasing significant growth and improvements. The company achieved a 25% revenue increase in Q4 and a $0.5M Adjusted EBITDA profit, marking a substantial recovery from losses in the previous year. Additionally, operational efficiencies led to a 42% reduction in operating expenses. However, the cancellation of the Oranim agreement impacted revenue, and the company reported a net loss increase, raising questions about its ability to continue as a going concern.
Read more →-IMCC
Mar 20, 2025▲ +6.6%on this news
IM Cannabis to Report Fourth Quarter and Full Year 2024 Financial Results on Monday, March 31 2025 at 9:00am ET
IM Cannabis Corp. is set to report its fourth quarter and full year 2024 financial results on March 31, 2025, prior to market opening. The announcement includes a web conference for investors at 9:00 a.m. ET, providing an opportunity for a Q&A session. IMC operates in key markets such as Israel and Germany, focusing on sustainable growth and compliance within the regulated cannabis industry. The company's commitment to transparency and investor engagement is evident in its forthcoming report and conference call.
Read more →-IMCC
Jan 17, 2025IM Cannabis Announces Change of Auditors
IM Cannabis Corp. has announced a change of auditors from Kost Forer Gabbay & Kasierer to Fahn Kanne & Co. Grant Thornton Israel, effective January 16, 2025. The transition was initiated at the Company's request, with the new auditor appointed upon the audit committee's recommendation. There were no reportable events or reservations in the previous auditor's reports. This change aligns with the company's ongoing focus on governance and compliance in its operations within the medical cannabis sector in Israel and Germany.
Read more →-IMCC
Nov 14, 2024IM Cannabis Reports Third Quarter Financial Results
IM Cannabis Corp. (IMCC) reported its financial results for Q3 2024, marking a 12% increase in revenue to $13.9 million, attributed mainly to significant growth in the German market. The company's operating expenses decreased by 16% to $4.1 million, resulting in an improved operational efficiency ratio. Despite these positive financial indicators, the company faced a net loss of $1.1 million and a decline in total assets by 8.6% compared to the end of 2023. Management emphasizes that their focus on building a strong foundation is geared towards improved performance in 2025.
Read more →-IMCC
Nov 12, 2024▲ +5.4%on this news· ran to +26% by day 3shared move
IM Cannabis Closes Non-Brokered Private Placement led by Management and Concurrent Debt Settlement
IM Cannabis Corp. has successfully closed a non-brokered private placement, raising C$2.14 million through the issuance of 742,517 units. The funds from the offering will be directed towards the repayment of a significant loan and include a concurrent debt settlement amounting to US$560,000. The involvement of company insiders in these transactions has raised potential governance issues, requiring future minority shareholder approval. The successful transaction aims to improve the company’s financial health amid ongoing financial challenges.
Read more →-IMCC
Nov 6, 2024▼ -10%on this news
IM Cannabis to Report Third Quarter 2024 Financial Results on Thursday, November 14th at 9:00am ET
IM Cannabis Corp. will announce its financial results for Q3 2024 on November 14, 2024, before the market opens. A web conference is scheduled for the same day at 9:00am ET, where company representatives will discuss the results and answer questions from investors. IMC is focused on the medical cannabis markets in Israel and Germany, emphasizing its commitment to sustainable growth and compliance with regulations.
Read more →-IMCC
Oct 4, 2024IM Cannabis Announces up to US$1,613,000 Private Placement Offering Led by Management
IM Cannabis Corp. announced plans for a non-brokered private placement to raise up to US$1,613,000. The offering will be led by management and involve the sale of approximately 625,000 units, each consisting of one share and one warrant. The company plans to use the funds primarily to repay a previous loan. Despite this positive development, the company has also cancelled many options and warrants which raises questions about incentive alignment.
Read more →-IMCC
Oct 2, 2024IMC Germany Announces Outstanding Preliminary Q3, 2024 Performance with 50% Growth Over Q2
IM Cannabis Corp. (IMCC) announced remarkable preliminary sales results for its German subsidiary, Adjupharm GmbH, showing a 50% revenue increase for Q3 2024 compared to Q2. This growth highlights the strong market demand for cannabis products following the partial legalization in Germany. CEO Oren Shuster emphasized the company's commitment to maintaining a robust supply chain to meet this demand. The results not only exceeded the company's internal targets but also reflect the effectiveness of their strategic initiatives.
Read more →-IMCC
Sep 11, 2024IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors
IM Cannabis Corp. has appointed Shmulik Arbel to its Board of Directors, effective September 9, 2024. Arbel brings over 25 years of experience from Leumi, Israel's largest banking group, which is anticipated to strengthen IMC's strategic and financial growth. The CEO of IMC expressed optimism about Arbel's ability to guide the company as it aims to solidify its presence in the medical cannabis sector in Israel and Germany. Arbel holds a BA and MBA from Tel Aviv University.
Read more →-IMCC
Aug 14, 2024▲ +8.3%on this news
IM Cannabis Reports Second Quarter Financial Results
IM Cannabis Corp. reported a 12% increase in revenue for Q2 2024, reaching $14.8 million, driven predominantly by a remarkable 200% growth in sales from its German operations following the country's cannabis legalization. Although the financial results show growth, the gross margin significantly decreased to 6%, primarily due to inventory clearance issues. The company's net loss narrowed slightly to $3.5 million from $3.7 million year-over-year, while operating expenses decreased by 29%. These results highlight both the challenges and opportunities in the evolving cannabis market.
Read more →-IMCC
Aug 6, 2024▲ +10.8%on this news
IM Cannabis to Report Second Quarter 2024 Financial Results on Wednesday, August 14th at 9:00am ET
IM Cannabis Corp. (NASDAQ: IMCC) will announce its financial results for the second quarter of 2024 on August 14, 2024, before the market opens. A Zoom web conference is scheduled for the same day at 9:00 AM ET, allowing investors to discuss the results and ask questions. The company is focused on its operations in Israel and Germany, aiming to achieve sustainable growth in these key markets.
Read more →-IMCC
Jul 29, 2024IM Cannabis Receives NASDAQ Notification of Regaining Compliance with Nasdaq
IM Cannabis Corp. announced that it has received formal notice from Nasdaq confirming its compliance with the minimum bid price requirement. The company had previously been notified of non-compliance last August but has since shown a closing bid price of $1.00 or greater for the last ten consecutive business days, thus regaining compliance. IM Cannabis operates in the medical cannabis markets of Israel and Germany, providing premium products and services to medical patients. The company's compliance allows it to remain listed on the Nasdaq Stock Market.
Read more →-IMCC
Jul 12, 2024▲ +11.6%on this news· ran to +24% by day 1
IM Cannabis Shares Commence Trading on 6:1 Consolidated Basis
IM Cannabis Corp. announced that its shares began trading on a 6:1 consolidated basis on both the Canadian Securities Exchange and NASDAQ as of July 12, 2024. This move reduces the number of common shares from approximately 13.4 million to about 2.2 million, with fractional shares cancelled or rounded to whole numbers. All outstanding convertible securities' prices and quantities were adjusted accordingly. The company is focused on sustainable growth in the medical cannabis markets of Israel and Germany.
Read more →-IMCC
Jul 5, 2024▼ -10.3%on this news· ran to -24% by day 1
IM Cannabis Announces Intention to Complete Consolidation
IM Cannabis Corp. has announced a share consolidation plan, converting every six of its current shares into one post-consolidated share, effective July 12, 2024. The company anticipates that this move will enhance market perception and align its share count with industry standards. This consolidation, while potentially beneficial, carries risks related to the regulatory landscape and market conditions as the company aims to strengthen its operations in Israel and Germany, two major cannabis markets.
Read more →-IMCC
Jun 5, 2024▼ -6.9%on this news
IMCC Addresses Accelerated Growth in Germany Through new Supply Agreement with EU-GMP Certified Glasshouse Botanics and Announces a Change to its Board of Directors
IM Cannabis Corp. (IMCC) announced it is accelerating growth in Germany following the recent partial legalization of cannabis. With a new supply agreement with GlassHouse Botanics, the company aims to enhance its supply chain capabilities to meet increasing demand. IMC Germany achieved impressive growth in 2023, significantly outperforming the market. Additionally, the company has made changes to its Board of Directors, appointing Oren Shuster as the new Chairman.
Read more →-IMCC
May 29, 2024IM Cannabis Closes Convertible Debenture Offering to Support Accelerated Growth in Germany
IM Cannabis Corp. has closed a $2.09 million convertible debenture offering aimed at supporting its growth in Germany following the recent legalization of medicinal cannabis. The company has reduced its general and administrative costs by 49% in 2023, but faces financial risks stemming from the structure of the debentures and related party transactions. CEO Oren Shuster highlights a focus on renegotiating debt to lower financing costs. The offering may enhance IMC's financial position as it pivots resources toward the burgeoning German market.
Read more →-IMCC
May 28, 2024IMC announces the termination of a preliminary term sheet with Kadimastem Ltd., a public company traded on the Tel Aviv Stock Exchange to fully focus on the recently legalized German market
IM Cannabis Corp. has announced the termination of a preliminary term sheet with Kadimastem Ltd., directing its focus towards the newly legalized German market. The company expressed optimism about significant growth in Germany following legalization in April 2024. IMC aims to maximize shareholder value and capitalize on the emerging market. This decision includes a repayment obligation of $300,000 to Kadimastem by July 31, 2024, indicating possible financial implications for the company.
Read more →-IMCC
May 1, 2024▲ +29.1%on this news
IM Cannabis to Report First Quarter 2024 Financial Results on Wednesday, May 8th at 9:00am ET
IM Cannabis Corp. (CSE: IMCC) is scheduled to report its financial results for the first quarter of 2024 on May 8, 2024, before market opening. The company will host a Zoom web conference at 9:00 am ET to discuss these results and engage in a Q&A session with investors. IMC has recently exited the Canadian market to prioritize operations in Israel and Germany and aims for sustainable growth in these regions.
Read more →-IMCC
Apr 16, 2024▼ -10.9%on this news
IMC to transfer its Oranim Pharmacy shares back to the seller
IM Cannabis Corp. (IMCC) announced plans to transfer its 51% shares of Oranim Pharmacy back to the seller after opting not to complete remaining installment payments. CEO Oren Shuster highlighted the company's strategic focus on the burgeoning German market following recent cannabis legalization. This decision follows the company's exit from Canada, allowing it to allocate resources more effectively between its primary markets in Israel and Germany. The company is committed to achieving sustainable growth amidst these transitions.
Read more →-IMCC
Apr 4, 2024▲ +10.9%on this news
Avant and IMC Execute BLK MKT™ Trademark Licensing Agreement for the German Medical Cannabis Market
IM Cannabis Corp. has signed a licensing agreement with Avant Brands for the exclusive use of the BLK MKT™ brand in the German medical cannabis market. This collaboration will see IMC Germany distribute high-quality cannabis products cultivated by Avant, marking a significant step in their partnership. The agreement comes shortly after recent legalization of medical cannabis in Germany, which both companies anticipate will boost their market position. IMC's focus remains on providing premium products and expanding their footprint in Germany and Israel.
Read more →-IMCC
Apr 1, 2024▲ +40%on this news· ran to +104% by day 3shared move
IMC applauds the April 1st implementation of the new Israeli cannabis regulation, facilitating access for many new patients
IM Cannabis Corp. (IMCC) has welcomed the implementation of new medical cannabis regulations in Israel as of April 1st, which aims to increase patient access. The reform will simplify the prescription process and allow medical cannabis to be prescribed through the public healthcare system, significantly increasing the number of eligible patients. Notably, it will also reduce the costs associated with prescriptions, while more physicians are expected to become licensed to prescribe cannabis. Overall, these changes position IMC to potentially expand its market and enhance patient care.
Read more →-IMCC
Mar 28, 2024▲ +28.9%on this news· ran to +137% by day 3shared move
IM Cannabis Reports 2023 Financial Results
IM Cannabis Corp. reported financial results for the year ending December 31, 2023, highlighting a 10% decrease in revenue to $48.8 million, attributed mainly to negative currency effects and the impact of the Israel-Hamas war. Despite the challenges, the company saw a gross profit increase of 7.5% for the year, although fourth-quarter gross profit fell significantly. Management remains hopeful about growth opportunities in the German market and is actively pursuing a reverse merger with Kadimastem Ltd.
Read more →-IMCC
Mar 25, 2024IMC Expects Accelerated Growth in Germany from the Country
IM Cannabis Corp. (IMCC) anticipates accelerated growth in the German medical cannabis market following new regulations that will classify cannabis as a standard prescription. The company reported a substantial growth of 180% in 2023, outpacing the overall market growth of 20%. With the final approval of cannabis legalization in Germany, IMC aims to leverage its established infrastructure and supply agreements to further expand its operations and delivery capabilities. The regulatory changes, effective April 1st, are expected to enhance patient access and stimulate market growth.
Read more →-IMCC
Mar 20, 2024IM Cannabis to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 28 at 9:00am ET
IM Cannabis Corp. (CSE: IMCC, NASDAQ: IMCC) will report its financial and operational results for the fourth quarter and full year of 2023 on March 28, 2024, before market opening. The company will host a web conference at 9:00 AM ET to discuss the results and engage with investors. IM Cannabis has recently shifted its focus to the high-value medical cannabis markets in Israel and Germany after discontinuing its operations in Canada.
Read more →-IMCC
Feb 28, 2024▼ -5.1%on this news
IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company
IM Cannabis Corp. (IMC) has announced a potential reverse merger with Israeli clinical cell therapy company Kadimastem. This transaction, which aims for completion under a non-binding term sheet, will shift IMC's focus from medical cannabis to biotechnology, with Kadimastem shareholders holding a majority stake in the new entity. Kadimastem is currently developing products for diabetes and ALS treatment and has received FDA approval for a Phase IIa trial. However, the merger is contingent upon certain regulatory approvals and other conditions, which could impact the timing and success of the deal.
Read more →-IMCC
Jan 31, 2024▼ -9%on this news
IM Cannabis Receives 180 Calendar Day Extension from the Nasdaq Stock Market to Regain Compliance with Bid Price Rule
IM Cannabis Corp. announced it has received a 180-calendar day extension from Nasdaq to comply with the Bid Price Rule, which requires its shares to maintain a bid price of at least $1.00 for 10 consecutive days. The original compliance deadline was January 29, 2024, but the new deadline is now July 29, 2024. The company will monitor its stock price and may consider options such as a reverse stock split to meet the compliance requirements. This extension allows IM Cannabis to concentrate on its core markets while pursuing strategies for sustainable growth.
Read more →-IMCC
Jan 12, 2024▲ +5%on this news
IMC Reschedules the Final Payment of the Oranim Pharmacy Acquisition
IM Cannabis Corp. has announced the rescheduling of the final payment for the acquisition of Oranim Pharmacy to April 15, 2024. Originally due on February 15, 2024, this change is part of an amendment made on January 10, 2024. The outstanding payments will incur a 15% interest charge, and failure to complete these payments may lead to the loss of IMC Holdings Ltd. shares back to the seller. This news comes as IMC continues to refocus on its operations in Israel and Germany after exiting the Canadian market.
Read more →-IMCC
Jan 2, 2024IMC Announces the Conclusion of the Planning and Construction Legal Proceedings
IM Cannabis Corp. has concluded legal proceedings against Focus Medical Herbs Ltd., maintaining control over the company. This development allows IMC to continue its operations unaffected, focusing on the importation and sale of its premium cannabis brands. CEO Oren Shuster described the outcome as the best possible scenario, highlighting a strategic shift towards sustainable growth in Israel and Germany following the closure of the cultivation facility in June 2022. IMC aims to capitalize on high-value markets after exiting Canadian operations.
Read more →-IMCC
Dec 8, 2023New Israeli cannabis regulation, facilitating access for many new patients, scheduled for December 29, 2023, has been postponed by three months; Israeli Ministry of Health published a new report showing a surge in new medical cannabis patients in November 2023
IM Cannabis Corp. has announced a three-month delay in the implementation of the Israeli medical cannabis regulatory reform initially slated for December 29, 2023, due to the ongoing Israel-Hamas conflict. This reform is expected to relax restrictions and improve access for medical cannabis patients. However, the Israeli Ministry of Health released a report revealing an increase in new medical cannabis licenses, with November 2023 seeing 3,254 new patients, the highest monthly increase since 2021. Despite the regulatory delay, there are promising signs of growth within the medical cannabis sector in Israel.
Read more →-IMCC
Nov 27, 2023IM Cannabis Announces Receipt of Court Action
IM Cannabis Corp. is facing a lawsuit in the Ontario Superior Court of Justice related to alleged misrepresentations before a 2021 transaction. The plaintiffs, comprising MYM Shareholder Plaintiffs, are seeking approximately $15 million in damages. In response, IMC asserts that these allegations are without merit and intends to contest the claims. The company has recently refocused its operations away from Canada to concentrate on key markets in Israel and Germany.
Read more →-IMCC
Nov 13, 2023IM Cannabis Reports Third Quarter 2023 Financial Results
IM Cannabis Corp. reported its Q3 2023 financial results, showing a 6.6% decrease in revenue, largely influenced by currency fluctuations. Despite this, gross profit rose by 30% and operating expenses were cut by 34%, indicating progress in cost management efforts. The company remains focused on achieving sustainable profitability and has strengthened its position in the premium market segment in Israel. Management has noted potential impacts from ongoing regional tensions on the cannabis market.
Read more →-IMCC
Nov 8, 2023IM Cannabis to Report Third Quarter 2023 Financial Results on Monday, November 13 at 9:00am ET
IM Cannabis Corp. will announce its third quarter 2023 financial results on November 13, 2023, prior to market opening. A Zoom web conference will follow at 9:00 a.m. ET for discussions and Q&A with investors. IMC is now focusing its operations on the more lucrative medical cannabis markets in Israel and Germany after exiting Canada. This pivot reflects their strategy for sustainable growth and compliance in competitive markets.
Read more →-IMCC
Oct 13, 2023▲ +7%on this news
IM Cannabis Releases a Message from the CEO about the Israel-Hamas War and announces securing C$1,390,000 in Short-Term Debt
IM Cannabis Corp. announced that it has secured C$1,390,000 in short-term debt through its subsidiaries amid the Israel-Hamas War. CEO Oren Shuster spoke about the profound impact of the ongoing conflict on the local community and expressed support for affected Israelis. The funds raised will be used for general working capital, as the company operates within the medical cannabis sector, deemed critical infrastructure in Israel. However, the business faces potential operational risks and high-interest obligations linked to these loans.
Read more →-IMCC
Oct 10, 2023IM Cannabis Announces the appointment of Uri Birenberg as Chief Financial Officer
IM Cannabis Corp. has announced the appointment of Uri Birenberg as its new Chief Financial Officer, effective October 10, 2023. This strategic move is anticipated to enhance the company's financial leadership and guide its efforts towards sustainable profitability. Birenberg brings over two decades of financial experience and is expected to contribute significantly to achieving IMC's strategic goals. He follows Itay Vago, who will be transitioning from the role after the Q3 2023 results are presented in November.
Read more →-IMCC
Sep 19, 2023▼ -7.7%on this news
IM Cannabis Announces CFO Departure
IM Cannabis Corp. announced the departure of its Chief Financial Officer Itay Vago for personal reasons. Vago will continue in his role until the Q3 2023 publication, during which the company will search for a new CFO. CEO Oren Shuster expressed appreciation for Vago's contributions, noting his valuable role over the past year. The company is currently pivoting its focus to the Israeli and German markets after exiting its operations in Canada.
Read more →-IMCC
Aug 11, 2023IMC welcomes new Israeli cannabis regulations which are about to change significantly, facilitating access for many new patients
The Israeli Ministry of Health announced a significant regulatory reform for medical cannabis on August 7, 2023. The new rules will allow patients with various medical conditions to obtain cannabis with a regular prescription instead of a license, expected to commence on December 29, 2023. The changes will also enable cannabis to be utilized as a first-line treatment, enhancing its availability and use among patients. IM Cannabis Corp. expressed optimism regarding these reforms, highlighting potential for increased patient access and export opportunities to Europe.
Read more →-IMCC
Aug 8, 2023IM Cannabis to Report Second Quarter 2023 Financial Results on Monday, August 14 at 9:00am ET
IM Cannabis Corp. will report its second quarter 2023 financial results on August 14, 2023, before the market opens. Following the release, a web conference will be hosted at 9:00 a.m. ET to discuss the results and engage with investors. The company has recently exited the Canadian market to focus on its operations in Israel and Germany, which are key markets for its medical cannabis products.
Read more →-IMCC
Aug 4, 2023IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
IM Cannabis Corp. received a notification from Nasdaq regarding its non-compliance with the minimum bid price requirement, as its shares have been below $1.00 for 30 consecutive business days. The company has until January 29, 2024, to regain compliance by reaching the minimum closing bid price. This notification does not currently affect its listing status, but failing to meet the requirement may result in potential delisting. The company is focusing its operations on markets in Israel and Germany after exiting Canada.
Read more →-IMCC
May 15, 2023▲ +16.9%on this news
IM Cannabis Reports First Quarter 2023 Financial Results; Gross Profit Increased 46% Year-over-Year
IM Cannabis Corp. reported a robust financial performance for Q1 2023, with a 46% increase in gross profit and a significant reduction in operating expenses by 42%. Despite a stable revenue of $13.2 million, the company achieved a net loss reduction to zero, indicating progress towards profitability. However, challenges such as a drop in average selling prices due to increased competition were noted, along with a 6% decline in total assets compared to the prior quarter.
Read more →-IMCC
May 8, 2023IM Cannabis to Report First Quarter 2023 Financial Results on Monday, May 15 at 9:00am ET
IM Cannabis Corp. plans to report its financial results for the first quarter of 2023 on May 15, 2023, before the market opens. A zoom web conference will follow at 9:00 a.m. ET to discuss these results and engage with investors through a Q&A session. The company is pivoting its focus towards sustainable growth in Israel and Germany after exiting operations in Canada. IMC emphasizes compliance and a data-driven approach as part of its operational strategy.
Read more →-IMCC
May 8, 2023IM Cannabis Completes Debt Settlement with L5 Capital
IM Cannabis Corp. has successfully completed a debt settlement with L5 Capital, settling approximately $838,776 by issuing 492,492 units priced at $1.25 each. Each unit consists of a common share and a warrant exercisable at $1.50 for 36 months. This transaction is categorized as a related party transaction due to L5 Capital being controlled by an insider. Following the acquisition, L5 Capital now holds about 11.59% of IM Cannabis's common shares on a partially diluted basis.
Read more →-IMCC
Apr 28, 2023▲ +9.2%on this news
IM Cannabis Announces Units for Debt Settlement
IM Cannabis Corp. has announced a securities-for-debt settlement with L5 Capital, allowing the company to resolve approximately US$615,615 in debt through the issuance of units at US$1.25 per unit. Each unit includes a common share and a purchase warrant for additional shares at a price of US$1.50. The transaction, treated as a related party deal, is expected to close around May 5, 2023. This move aligns with IM Cannabis's strategy to focus on integrating operations in major medical cannabis markets, particularly in Israel and Germany.
Read more →-IMCC
Mar 15, 2023▲ +8.5%on this news
IM Cannabis to Report Fourth Quarter & Full Year 2022 Financial Results on Wednesday, March 29 at 9:00am ET
IM Cannabis Corp. will report its financial results for Q4 and the full year 2022 on March 29, 2023, before market opens. A web conference call will be held at 9:00 a.m. ET for discussion and Q&A with investors. The company is transitioning away from Canada to concentrate on growth opportunities in Israel and Germany. IMC emphasizes a data-driven approach and compliance with regulatory environments as it aims to solidify its market presence.
Read more →-IMCC
Mar 8, 2023IM Cannabis Announces Additional Restructuring Initiatives Designed to Drive Sustainable Profitability and Reduce Costs
IM Cannabis Corp. announced strategic restructuring initiatives aimed at achieving sustainable profitability in 2023, including a significant reduction of its workforce by 20%-25% in Israel. The company anticipates approximately CAD$3.5 million in annualized cost savings while maintaining expected revenue levels. The restructuring involves transitioning key leadership roles to capable internal candidates. Furthermore, IM Cannabis is exiting the Canadian market to refocus its efforts on growth opportunities in Israel, Germany, and Europe.
Read more →-IMCC
Feb 16, 2023IM Cannabis Closes Additional Tranche of LIFE Offering
IM Cannabis Corp. has successfully closed an additional tranche of its LIFE Offering, raising approximately US$632,247.50 through the issuance of 505,798 Units. This closing marks the final tranche in a larger fundraising effort that totaled over US$6.4 million. The proceeds will be utilized for general working capital needs as the company plans to shift focus from its Canadian operations toward growth in Israel and Germany. Additionally, a non-independent director participated in the funding, reflecting insider confidence in the company's direction.
Read more →-IMCC
Feb 13, 2023▲ +13.7%on this newsshared move
IM Cannabis Provides an Update on Panaxia Transaction
IM Cannabis Corp. has announced an update on its transaction with Panaxia, which involved acquiring home-delivery services and online retail operations in Israel. As part of the update, both companies agreed to terminate the Panaxia Pharmacy Option, which alleviates IMC from making a significant installment payment. In exchange for this termination, IMC will receive a compensation amount from Panaxia. The updated transaction is positioned to enhance IMC's operational efficacy in the Israeli market.
Read more →-IMCC
Feb 7, 2023▼ -6%on this news· ran to -23% by day 3
IM Cannabis Closes Additional Tranches of Private Placement Offerings
IM Cannabis Corp. has successfully closed additional tranches of its non-brokered private placement offering, resulting in significant gross proceeds exceeding $5.7 million. The company issued 760,450 units at a price of $1.25 each, contributing to a total of 4,639,621 units issued since the start of the offering. These proceeds are intended for general working capital as the company pivots its focus away from Canada towards its operations in Israel and Germany. The offering was conducted under specific exemptions due to regulatory constraints on U.S. sales.
Read more →-IMCC
Jan 31, 2023▲ +6.8%on this news
IM Cannabis Closes Third Tranche of LIFE Offering
IM Cannabis Corp. has successfully closed the third tranche of its LIFE Offering, raising approximately $1.45 million through 1,162,000 units. This marks a total of approximately $4.35 million raised under the LIFE Offering and a concurrent private placement. The company plans to use the proceeds for general working capital, while focusing its operations on the Israeli and German cannabis markets. Additionally, there is no statutory hold period for the newly issued shares, enhancing their market trading potential.
Read more →-IMCC
Jan 20, 2023IM Cannabis Closes Second Tranche of Private Placement Offerings
IM Cannabis Corp. has successfully closed a second tranche of its non-brokered private placement offering, raising US$946,465 by issuing 757,172 units. Each unit comprises a common share and a warrant, which can be exercised for additional shares at an exercise price of US$1.50 over 36 months. The company aims to utilize the proceeds for general working capital, while also transitioning focus from Canadian operations to enhance growth in Israel and Germany. Notably, a related party transaction involved a director subscribing for units in exchange for debt settlement.
Read more →-IMCC
Jan 17, 2023RAFAEL GABAY ACQUIRES SECURITIES OF IM CANNABIS CORP.
Rafael Gabay, a significant shareholder in IM Cannabis Corp., has acquired 303,295 common shares and an equal number of warrants in a recent private placement. Following this acquisition, Gabay's total ownership in the company has risen to approximately 12.9% of the issued and outstanding shares. The acquisition was made for general investment purposes, and Gabay may consider further actions in the future based on market conditions. This transaction required the filing of an early warning report in accordance with Canadian Securities regulations.
Read more →-IMCC
Jan 17, 2023OREN SHUSTER ACQUIRES SECURITIES OF IM CANNABIS CORP.
Oren Shuster, CEO of IM Cannabis Corp., has acquired 856,704 common shares and warrants through a private placement, totaling approximately $1.07 million. Following this acquisition, his ownership in the company has risen to 20.5%. This move represents Shuster's intention to solidify his investment in IMCC, reflecting confidence in the company's potential growth. The acquisition also triggers an early warning report due to the significant increase in his shareholding.
Read more →-IMCC
Nov 17, 2022▼ -19.7%on this news
IM Cannabis Common Shares Commence Trading on Consolidated Basis After 1 for 10 Reverse Stock Split
GLIL YAM, Israel, Nov. 17, 2022 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, announced today that further to the press release dated November 14, 2022, all of its issued and outstanding common sh
Read more →-IMCC
Nov 14, 2022IM Cannabis Reports Third Quarter 2022 Financial Results; Revenues Increased 78% YoY and 12% Sequentially
Company to refocus resources and efforts on the Israeli and German markets; Commences exit of the Canadian market TORONTO and GLIL YAM, Israel, Nov. 14, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company", "IM Cannabis", or "IMC") (CSE: IMCC) (NASDAQ: IMCC), a leading medical
Read more →-IMCC
Oct 11, 2022Filed by newsfilecorp.com NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES IM Cannabis Announces USD$5,000,000 Private Placement Toronto, Ontario and Glil Yam, Israel
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES IM Cannabis Announces USD$5,000,000 Private Placement Toronto, Ontario and Glil Yam, Israel - August 19, 2022 - IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ: IMCC) (C
Read more →-IMCC
Oct 6, 2022▲ +9.7%on this newsshared move
IM Cannabis Closes Second Tranche of Non-Brokered Private Placement of Common Shares
Marc Lustig, Executive Chairman of the Company Subscribes for 1,112,504 common shares at USD$0.50 TORONTO and GLIL YAM, Israel, Oct. 6, 2022 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ: IMCC) (CSE: IMCC), a leading medical and adult-use recreationa
Read more →-IMCC
Oct 5, 2022▲ +5.9%on this news· ran to +16% by day 1shared move
Filed by newsfilecorp.com IM Cannabis Closes Second Tranche of Non-Brokered Private Placement of Common Shares Marc Lustig, Executive Chairman of the Company Subscribes for 1,112,504 common shares at USD$0.50 TORONTO and
IM Cannabis Closes Second Tranche of Non-Brokered Private Placement of Common Shares Marc Lustig, Executive Chairman of the Company Subscribes for 1,112,504 common shares at USD$0.50 TORONTO and GLIL YAM, Israel, October 5, 2022 - IM Cannabis Corp. ("IM Cannabis" or the "Compa
Read more →-IMCC
Sep 12, 2022Filed by newsfilecorp.com Date
Date: September 12, 2022 510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: IM CANNABIS CORP. We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Iss
Read more →-IMCC
Sep 8, 2022▲ +7.7%on this newsshared move
RAFAEL GABAY ACQUIRES COMMON SHARES OF IM CANNABIS CORP.
TORONTO and GLIL YAM, Israel, Sept. 8, 2022 /PRNewswire/ -- Rafael Gabay, a promoter and significant shareholder of IM Cannabis Corp. ("IMCC" or the "Company") (CSE: IMCC) (NASDAQ: IMCC), announces that he has acquired an aggregate of 613,496 common shares in the capital of IMCC
Read more →-IMCC
Aug 24, 2022▲ +6.7%on this news
Filed by newsfilecorp.com NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES IM Cannabis Closes First Tranche of Non-Brokered Private Placement of Common Shares Toronto, Ont
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES IM Cannabis Closes First Tranche of Non-Brokered Private Placement of Common Shares Toronto, Ontario and Glil Yam, Israel - August 24, 2022 - IM Cannabis Corp. ("IM Cannabis" or th
Read more →-IMCC
Aug 22, 2022Filed by newsfilecorp.com FORM 6 CERTIFICATE OF COMPLIANCE TO: CANADIAN SECURITIES EXCHANGE ("CSE") IM Cannabis Corp. (the "Listed Issuer") hereby certifies to CSE that the Issuer is in compliance with the requirements o
CERTIFICATE OF COMPLIANCE TO: CANADIAN SECURITIES EXCHANGE ("CSE") IM Cannabis Corp. (the "Listed Issuer") hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101)
Read more →-IMCC
Aug 15, 2022IM Cannabis Reports Record Second Quarter 2022 Financial Results; Revenues Increase 114% YoY to $23.8 Million
Gross margin of 24%, which is expected to increase with further asset integration, product availability, and operational improvements Approximately $6.5 million per year in expected cash cost savings from streamlining operations in Canada and closure of Israeli cultivation farm
Read more →-IMCC
Aug 12, 2022▲ +18.8%on this newsshared move
Filed by newsfilecorp.com 510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9
510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 August 12, 2022 www.computershare.com To: All Canadian Securities Regulatory Authorities NASDAQ Exchange Subject: IM CANNABIS CORP. We advise of the following with respect to the upcoming Meeting of Security Holders for the sub
Read more →-IMCC
Aug 4, 2022▲ +8.9%on this news· ran to +30% by day 1
IM Cannabis to Report Second Quarter 2022 Financial Results on Monday, August 15 at 9:00am ET
TORONTO and GLIL YAM, Israel, Aug. 4, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE: IMCC) (NASDAQ: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, will report operational and fina
Read more →-IMCC
May 12, 2022▲ +10%on this news
IM Cannabis Reports Record First Quarter 2022 Financial Results; Revenues Increase 169% YoY to $23.6 Million
Gross Profit Increased 37% from Q1 2021 as Operational Efficiencies from Integration Take Hold; Company Expects to Achieve Positive Adjusted EBITDA in Q2 2022 TORONTO and GLIL YAM, Israel, May 12, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company", "IM Cannabis", or "IMC") (C
Read more →-IMCC
May 5, 2022IM Cannabis to Report First Quarter 2022 Financial Results on Thursday, May 12 at 5:00 p.m. ET
TORONTO, Canada and GLIL YAM, Israel, May 5, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE: IMCC) (NASDAQ: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, will report operational a
Read more →-IMCC
Apr 12, 2022▼ -7.7%on this news· ran to -18% by day 3
OREN SHUSTER ACQUIRES COMMON SHARES OF IM CANNABIS CORP.
TORONTO and GLIL YAM, Israel, April 12, 2022 /PRNewswire/ -- Oren Shuster, CEO, director and founder of IM Cannabis Corp. ("IMCC" or the "Company") (CSE: IMCC) (NASDAQ: IMCC), announces that he has acquired an aggregate of 150,000 common shares in the capital of IMCC (the "Common
Read more →-IMCC
Apr 6, 2022IM Cannabis Strengthens Focus on Importing Premium and Ultra-Premium Products from its Canadian Subsidiaries
Closure of Sde Avraham farm in Israel optimizes Company's organizational structure by fully leveraging global import-export supply chain Increase in Revolving Credit Facility availability to $15 million supports increased global demand for premium cannabis TORONTO, Canada and G
Read more →-IMCC
Mar 31, 2022▼ -10.5%on this news
IM Cannabis Reports Record Fourth Quarter and Fiscal Year 2021 Financial Results and Provides First Quarter 2022 Outlook
- Fiscal Year 2021 revenues increased 242% year-over-year to a record of over $54 million - Q4 2021 revenues increased 309% year-over-year and 39% compared to Q3 2021 - Sequential revenue growth and gross margin improvement expected in Q1 2022 TORONTO, and GLIL YAM, Israel, Ma
Read more →-IMCC
Mar 30, 2022▲ +9.4%on this newsshared move
IM Cannabis Closes Previously Announced Acquisition of Oranim Pharm, Jerusalem
Transaction expands IMC's footprint into Israel's largest city while positioning the Company as one of the largest retailers of medical cannabis in the country TORONTO, and GLIL YAM, Israel, March 30, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:
Read more →-IMCC
Mar 29, 2022▲ +5.6%on this newsshared move
IM Cannabis Reschedules Fourth Quarter and Full Year 2021 Conference Call to Thursday, March 31 at 9:00 a.m. ET
TORONTO and GLIL YAM, Israel, March 29, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE: IMCC, NASDAQ: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, has rescheduled the release of
Read more →-IMCC
Mar 23, 2022IM Cannabis to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, March 30 at 9:00 a.m. ET
TORONTO and GLIL YAM, Israel, March 23, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE: IMCC, NASDAQ: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, will report operational and fin
Read more →-IMCC
Mar 15, 2022IM Cannabis Closes Three Previously Announced Strategic Acquisitions in Israel
TORONTO and GLIL YAM, Israel, March 15, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE: IMCC) (NASDAQ: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, has completed three strategic
Read more →-IMCC
Mar 10, 2022IM Cannabis Reports Record Preliminary Fourth Quarter and Full Year 2021 Financial Results
TORONTO and GLIL YAM, Israel, March 10, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company", "IM Cannabis", or "IMC") (CSE: IMCC) (NASDAQ: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, provided preliminary u
Read more →-IMCC
Feb 8, 2022IM Cannabis Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
TORONTO, ON and GLIL YAM, Israel, Feb. 8, 2022 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC) ("IM Cannabis" or the "Company"), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, has engaged international in
Read more →-IMCC
Jan 19, 2022IM Cannabis announces Focus Medical's Import of 400 Kilograms of Premium-Indoor-Grown Dried Cannabis from Canada to Israel The successful import demonstrates the strength of the IM Cannabis global supply chain and busine
imcc_ex991.htm EXHIBIT 99.1 IM Cannabis announces Focus Medical's Import of 400 Kilograms of Premium-Indoor-Grown Dried Cannabis from Canada to Israel The successful import demonstrates the strength of the IM Cannabis global supply chain and business model Toronto, Canada and
Read more →-IMCC
Jan 13, 2022IM Cannabis Corp. Appoints Rinat Efrima as New Chief Executive Officer of IMC Holdings, the Company's Israeli Subsidiary Oren Shuster remains Chief Executive Officer and Director of IM Cannabis Corp.; other managerial ch
PRESS RELEASE DATED JANUARY 13, 2022 imcc_ex991.htm EXHIBIT 99.1 IM Cannabis Corp. Appoints Rinat Efrima as New Chief Executive Officer of IMC Holdings, the Company's Israeli Subsidiary Oren Shuster remains Chief Executive Officer and Director of IM Cannabis Corp.; other manag
Read more →-IMCC
Jan 10, 2022Filed by newsfilecorp.com FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 31/12/2021: 68,217,894 Common
MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 31/12/2021: 68,217,894 Common Shares Date: January 10, 2022 1. Provide a general overview and discussion of the devel
Read more →-IMCC
Dec 30, 2021Filed by newsfilecorp.com FORM 11 NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer"). Trading Symbol: IMCC Date
NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer"). Trading Symbol: IMCC Date: December 30, 2021 1. New Options Granted: Date of Grant: December 27, 2021 Position (Director/ Officer/ No. of Employee/
Read more →-IMCC
Dec 7, 2021Filed by newsfilecorp.com FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 30/11/2021: 68,184,163 Common
MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 30/11/2021: 68,184,163 Common Shares Date: December 7, 2021 1. Provide a general overview and discussion of the devel
Read more →-IMCC
Dec 7, 2021IM Cannabis to Launch WAGNERS Brand in Germany IM Cannabis expects to export premium, indoor-grown Canadian cannabis in 2022 to the rapidly evolving German medical cannabis market Toronto, Canada; Glil Yam, Israel and Ba
IM Cannabis to Launch WAGNERS Brand in Germany IM Cannabis expects to export premium, indoor-grown Canadian cannabis in 2022 to the rapidly evolving German medical cannabis Toronto, Canada; Glil Yam, Israel and Bad Oldesloe, Germany December 7, 2021 IM Cannabis Corp. (the Co
Read more →-IMCC
Dec 1, 2021Filed by newsfilecorp.com FORM 9 NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES (or securities convertible or exchangeable into listed securities) Name of Listed Issuer: Symbol(s): IM Cannabis Corp. (the "I
NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES (or securities convertible or exchangeable into listed securities) Date: December 1, 2021 Is this an updating or amending Notice: Yes No If yes provide date(s) of prior Notices: __________________. Issued and Outst
Read more →-IMCC
Dec 1, 2021IM Cannabis to Acquire Oranim, Jerusalem's Leading Medical Cannabis Pharmacy Transaction positions IM Cannabis as one of the largest retailers of medical cannabis in Israel; Retail segment combined annualized revenue of
Cannabis to Acquire Oranim, Jerusalem's Transaction positions IM Cannabis as one of the largest retailers cannabis in Israel; Retail segment combined annualized revenue approximately $44 million Oranim's trailing 12-month revenue approximately $16.5 margin approximately 25%1
Read more →-IMCC
Nov 29, 2021IM Cannabis announces Focus Medical's Receipt of Israeli Ministry of Health Import Permit; Plans to Launch WAGNERS Brand in Israel IM Cannabis' popular recreational cannabis brand WAGNERS will be available in Israel in 2
IM Cannabis announces Focus Medical's Receipt of Israeli Ministry of Health Import Permit; Plans to Launch WAGNERS Brand in IM Cannabis' popular recreational cannabis brand WAGNERS will be available in Israel in 2022, enhancing IM Cannabis' presence in the market Toronto, Ca
Read more →-IMCC
Nov 24, 2021▲ +37.8%on this newsshared move
IM CANNABIS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 UNAUDITED IM CANNABIS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 CANADIAN DOLLARS IN
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 CANADIAN DOLLARS IN THOUSANDS Page Condensed Interim Consolidated Statements of Financial Position 3 - 4 Condensed Inter
Read more →-IMCC
Nov 23, 2021IM Cannabis Announces Fourth Installment of Shares in Connection with the Panaxia Transaction Toronto, Canada and Glil Yam, Israel – November 18 2021 IM Cannabis Corp . (the “Company” or “IM C
IM Cannabis Announces Fourth Installment of Shares in Connection with the Panaxia Transaction Canada and Glil Yam, Israel November 18 2021 IM Cannabis Corp. (the Company or IM Cannabis ) (CSE: IMCC, NASDAQ: IMCC), a leading medical and adult-use recreational cannabis company
Read more →-IMCC
Nov 22, 2021Filed by newsfilecorp.com FORM 9 NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES (or securities convertible or exchangeable into listed securities) Name of Listed Issuer: Symbol(s): IM Cannabis Corp. (th
NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED (or securities convertible or exchangeable into listed securities) Name of Listed Issuer: Symbol(s): IM Cannabis Corp. (the "Issuer"). IMCC Date: November 22, 2021 Is this an updating or amending Notice: Yes No If yes provide
Read more →-IMCC
Nov 15, 2021IM Cannabis Announces Third Quarter 2021 Financial Results and Provides Outlook and Business Update Q3 2021 revenues of $14.4 million; a 30% increase from Q2 2021 Gross margin improved to 20% from 5.4% in Q2 2021; expect
IM Cannabis Announces Third Quarter 2021 Financial Results and Provides Outlook and Business Update Q3 2021 revenues of $14.4 million; a 30% increase from Q2 Gross margin improved to 20% from 5.4% in Q2 2021; expected to increase further in Q4 and into 2022 Canadian recreati
Read more →-IMCC
Nov 5, 2021▲ +17%on this news
Filed by newsfilecorp.com FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 31/10/2021: 67,838,041 Common
MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 31/10/2021: 67,838,041 Common Shares Date: November 5, 2021 1. Provide a general overview and discussion of the devel
Read more →-IMCC
Oct 20, 2021Filed by newsfilecorp.com FORM 9 NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES (or securities convertible or exchangeable into listed securities 1 ) Name of Listed Issuer: Symbol(s): IM Cannabis Corp. (the
NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES (or securities convertible or exchangeable into listed securities1) Name of Listed Issuer: Symbol(s): IM Cannabis Corp. (the "Issuer"). IMCC Date: October 20, 2021 Is this an updating or amending Notice: Yes No If
Read more →-IMCC
Oct 20, 2021IMC Announces Third Installment of Shares in Connection with the Panaxia Transaction Toronto, Canada and Glil Yam, Israel
IMC Announces Third Installment of Shares in Connection with the Canada and Glil Yam, Israel - October 20, 2021 IM Cannabis Corp. (the Company or IM Cannabis ) (CSE: IMCC, NASDAQ: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel,
Read more →-IMCC
Oct 6, 2021Filed by newsfilecorp.com FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 30/09/2021: 67,581,944 Common
MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 30/09/2021: 67,581,944 Common Shares, 7,362,759 Warrants Date: October 6, 2021 1. Provide a general overview and disc
Read more →-IMCC
Aug 17, 2021Filed by newsfilecorp.com IM CANNABIS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2021 UNAUDITED IM CANNABIS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2021 CANA
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS CANADIAN DOLLARS IN THOUSANDS Page Condensed Interim Consolidated Statements of Financial Position 3 - 4 Condensed Interim Consolidated Statements of Profit or Loss and Oth
Read more →-IMCC
Aug 9, 2021Filed by newsfilecorp.com FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 31/07/2021: 67,298,478 Common
MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 31/07/2021: 67,298,478 Common Shares, 7,362,759 Warrants Date: August 9, 2021 1. Provide a general overview and discu
Read more →-IMCC
Aug 3, 2021Filed by newsfilecorp.com IMC Announces Results of its Annual General and Special Meeting of Shareholders Toronto, Canada, Glil Yam, Israel
IMC Announces Results of its Annual General and Special Meeting of Shareholders Toronto, Canada, Glil Yam, Israel, August 3, 2021 - IM Cannabis Corp. ("IMC" or the "Company") (CSE: IMCC, NASDAQ: IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational ca
Read more →-IMCC
Jul 28, 2021Filed by newsfilecorp.com IMC Accelerates its Israeli Retail Position through Acquisition of Leading Retailer and Distributor Pharm Yarok and Rosen High Way Strategically located, best in class retailer with approximatel
IMC Accelerates its Israeli Retail Position through Acquisition of Leading Retailer and Distributor Pharm Yarok and Rosen High Way Strategically located, best in class retailer with approximately CAD$8 million in annualized revenue Purchase price of CAD$4.6 million Toronto, C
Read more →-IMCC
Jul 23, 2021Filed by newsfilecorp.com IM Cannabis Provides Update on German Operations and Financial Outlook Toronto, Canada; Bad Oldesloe, Germany; and Glil Yam, Israel
IM Cannabis Provides Update on German Operations and Financial Outlook Toronto, Canada; Bad Oldesloe, Germany; and Glil Yam, Israel - July 23, 2021 - IM Cannabis Corp. ("IMC" or the "Company") (CSE: IMCC, NASDAQ: IMCC), a multi-country operator ("MCO") in the medical and adult-u
Read more →-IMCC
Jul 9, 2021Filed by newsfilecorp.com IM Cannabis Closes Acquisition of MYM Nutraceuticals TORONTO, CANADA, and
IM Cannabis Closes Acquisition of MYM Nutraceuticals TORONTO, CANADA, and GLIL YAM, ISRAEL - July 9, 2021 - IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC, CSE: IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational cannabis sectors with oper
Read more →-IMCC
Jul 9, 2021Filed by newsfilecorp.com MYM Shareholders Overwhelmingly Approve Plan of Arrangement with IM Cannabis Highland Grow is currently profitable on an EBITDA basis, unlocks margin expansion and is expected to be immediately
MYM Shareholders Overwhelmingly Approve Plan of Arrangement Highland Grow is currently profitable on an EBITDA basis, unlocks margin expansion and is expected to be immediately accretive to IM Cannabis Super premium positioning, complementary brands, enhanced distribution and
Read more →-IMCC
Jul 8, 2021Filed by newsfilecorp.com FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 30/06/2021: 57,083,034 Common
MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 30/06/2021: 57,083,034 Common Shares, 7,362,759 Warrants 1. Provide a general overview and discussion of the developme
Read more →-IMCC
Jul 1, 2021Filed by newsfilecorp.com IM CANNABIS CORP. ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON WEDNESDAY, JULY 28, 2021 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS AND MANAGEMENT INFORMATIO
ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON WEDNESDAY, JULY 28, 2021 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS MANAGEMENT INFORMATION CIRCULAR This management information circular and the accompanying materials require your immediate at
Read more →-IMCC
Jun 28, 2021Filed by newsfilecorp.com IM Cannabis Proposed Acquisition of MYM Receives Positive Recommendations from Proxy Advisory Firms Glass Lewis and ISS Glass Lewis and Institutional Shareholder Services recommend that MYM shar
IM Cannabis Proposed Acquisition of MYM Receives Positive Recommendations from Proxy Advisory Firms Glass Lewis and ISS Glass Lewis and Institutional Shareholder Services recommend that MYM shareholders vote FOR Transaction with IMCC Over 90% of committed and tallied common sha
Read more →-IMCC
Jun 17, 2021Filed by newsfilecorp.com IM Cannabis Clinical Survey Confirms Effectiveness of Proprietary Strains in Alleviating Symptoms of Seven Key Health Conditions Conditions Evaluated Include Oncology, PTSD, Rheumatoid Arthritis
IM Cannabis Clinical Survey Confirms Effectiveness of Proprietary Strains in Alleviating Symptoms of Seven Key Health Conditions Conditions Evaluated Include Oncology, PTSD, Rheumatoid Arthritis, Chronic Pain, Insomnia, Back Pain and Inflammatory Bowel Diseases Conducted by L
Read more →-IMCC
Jun 11, 2021Filed by newsfilecorp.com FORM 5 QUARTERLY LISTING STATEMENT Name of Listed Issuer: IM Cannabis Corp (the "Issuer"). Trading Symbol: IMCC This Quarterly Listing Statement must be posted on or before the day on which the
QUARTERLY LISTING STATEMENT Name of Listed Issuer: IM Cannabis Corp (the "Issuer"). Trading Symbol: IMCC This Quarterly Listing Statement must be posted on or before the day on which the Issuer's unaudited interim financial statements are to be filed under the Securities Act,
Read more →-IMCC
Jun 7, 2021Filed by newsfilecorp.com IM Cannabis Announces Supply Agreement with Canadian LP The Flowr Corporation; Plan to Import Ultra-Premium Products as part of Enhanced Portfolio to Meet Growing Israeli Demand Toronto, Canada;
IM Cannabis Announces Supply Agreement with Canadian LP The Flowr Corporation; Plan to Import Ultra-Premium Products as part of Enhanced Portfolio to Meet Growing Israeli Demand Toronto, Canada; Glil Yam, Israel - June 7, 2021 - IM Cannabis Corp. (the "Company" or "IMC") (CSE: I
Read more →-IMCC
Jun 2, 2021Filed by newsfilecorp.com IMC Reports First Closing of the Panaxia Acquisition and Provides Update on Canadian Business Activities Launches WAGNERS brand with new cultivars and SKUs MYM shareholder meeting set for
IMC Reports First Closing of the Panaxia Acquisition and Provides Update on Canadian Business Activities Launches WAGNERS brand with new cultivars and SKUs MYM shareholder meeting set for July 5, 2021 Substantially completes loan portfolio run-off and realizes a 24% IRR Toron
Read more →-IMCC
May 18, 2021Filed by newsfilecorp.com IM CANNABIS CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of March 31, 2021 INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of March 31, 2021 Canadian dollars in thousands Page Interim Condensed Consolidated Statements of Financial Position 2 - 3 Interim Condensed Con
Read more →-IMCC
May 10, 2021Filed by newsfilecorp.com IM Cannabis Announces Closing of US$ 35 Million Equity Financing Toronto, Canada, Glil Yam, Israel
IM Cannabis Announces Closing of US$ 35 Million Equity Financing Toronto, Canada, Glil Yam, Israel, May 10, 2021 - IM Cannabis Corp. ("IMC" or the "Company") (CSE: IMCC, NASDAQ: IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational cannabis sector wit
Read more →-IMCC
May 5, 2021Filed by newsfilecorp.com IM Cannabis Announces Pricing of Proposed Public Offering of Securities Toronto, Canada, Glil Yam, Israel
IM Cannabis Announces Pricing of Proposed Public Offering of Securities Toronto, Canada, Glil Yam, Israel, May 5, 2021 - IM Cannabis Corp. ("IMC" or the "Company") (CSE: IMCC, NASDAQ: IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational cannabis sect
Read more →-IMCC
May 3, 2021Filed by newsfilecorp.com
Re: Business Acquisition Report dated April 28, 2021 Please be advised that we have refiled the business acquisition report dated April 28, 2021 (the "Business Acquisition Report") to amend the filing solely due to the missing date on the independent auditor's report of MNP LLP
Read more →-IMCC
Apr 30, 2021Filed by newsfilecorp.com IM Cannabis Acquires Israel's Largest Retail and Online Pharmacy Business from Panaxia, Creating a Vertically Integrated Global Platform for the IMC Brand With Israel's Fast-Paced E-Commerce Ado
IM Cannabis Acquires Israel's Largest Retail and Online Pharmacy Business from Panaxia, Creating a Vertically Integrated Global Platform for the IMC Brand With Israel's Fast-Paced E-Commerce Adoption and Cannabis Market's High Growth Rate (Averaging 4 Percent1 per Month), Panaxi
Read more →-IMCC
Apr 29, 2021Filed by newsfilecorp.com FORM 51-102F4 BUSINESS ACQUISITION REPORT Item 1 - Identity of Company 1.1 - Name and Address of Company This business acquisition report pertains to IM Cannabis Corp. (the " Company "), with a
BUSINESS ACQUISITION REPORT Item 1 - Identity of Company 1.1 - Name and Address of Company This business acquisition report pertains to IM Cannabis Corp. (the "Company"), with a head address located at Kibbutz Glil Yam, Central District, Israel 4690500 and a registered address
Read more →-IMCC
Apr 26, 2021Filed by newsfilecorp.com 2020 ANNUAL REPORT IM CANNABIS CORP. CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2020 CANADIAN DOLLARS IN THOUSANDS INDEX Page Report of Independent Registered Public Accounting Firm 2
CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2020 CANADIAN DOLLARS IN THOUSANDS Page Report of Independent Registered Public Accounting Firm 2 - 3 Consolidated Statements of Financial Position 4 - 5 Consolidated Statements of Profit or Loss and Other Comprehensive Inc
Read more →-IMCC
Apr 2, 2021Filed by newsfilecorp.com OPTION AGREEMENT This Option Agreement (the " Agreement ") is made and entered into as of April 2 nd 2019 (the " Effective Date "), by and among I.M.C Holdings Ltd. , a company duly incorporated
This Option Agreement (the "Agreement") is made and entered into as of April 2nd 2019 (the "Effective Date"), by and among I.M.C Holdings Ltd., a company duly incorporated under the laws of Israel, registration number XXXXXXXX, having its principal place of business at XXXXXX (th
Read more →-IMCC
Apr 1, 2021Filed by newsfilecorp.com FORM 9 NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES (or securities convertible or exchangeable into listed securities 1 ) Name of Listed Issuer: Symbol(s): Date
NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES (or securities convertible or exchangeable into listed securities1) Name of Listed Issuer: Symbol(s): Date: April 1, 2021 Is this an updating or amending Notice: Yes X No If yes provide date(s) of prior Notices:____
Read more →-IMCC
Mar 31, 2021Filed by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. - Name and Address of Company IM Cannabis Corp. (the " Company ") 550 Burrard St. #2300 Vancouver, BC, V6C 2B5 Item 2. - Date of Material Change
MATERIAL CHANGE REPORT Item 1. - Name and Address of Company IM Cannabis Corp. (the "Company") 550 Burrard St. #2300 Vancouver, BC, V6C 2B5 Item 2. - Date of Material Change Item 3. - News Release A press release disclosing the material change was released on April 1, 2021
Read more →-IMCC
Mar 18, 2021Filed by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 - Name and Address of Company IM Cannabis Corp. (the " Company ") 550 Burrard St. #2300 Vancouver, BC, V6C 2B5 Item 2 - Date of Material Change
MATERIAL CHANGE REPORT Item 1 - Name and Address of Company IM Cannabis Corp. (the "Company") 550 Burrard St. #2300 Vancouver, BC, V6C 2B5 Item 2 - Date of Material Change Item 3 - News Release A press release disclosing the material change was released on March 18, 2021 t
Read more →-IMCC
Mar 18, 2021Filed by newsfilecorp.com IMC Closes Acquisition of Trichome, Establishing Global Growth Platform in Both Adult Use and Medical Cannabis Markets TORONTO, ON and
IMC Closes Acquisition of Trichome, Establishing Global Growth Platform in Both Adult Use and Medical Cannabis Markets TORONTO, ON and GLIL YAM, ISRAEL, March 18, 2021 - IM Cannabis Corp. (the "Company" or "IMC") (CSE: IMCC), (NASDAQ: IMCC), a multi-country operator ("MCO") in
Read more →-IMCC
Mar 14, 2021Filed by newsfilecorp.com SECOND AMENDING AGREEMENT THIS SECOND AMENDING AGREEMENT (the " Second Amending Agreement ") is made as of
SECOND AMENDING AGREEMENT THIS SECOND AMENDING AGREEMENT (the "Second Amending Agreement") is made as of March 14, 2021. IM CANNABIS CORP., a company existing under the laws of the Province of British Columbia TRICHOME FINANCIAL CORP., a corporation existing under the laws of
Read more →-IMCC
Mar 12, 2021Filed by newsfilecorp.com IMC Announces Filing of Preliminary Short Form Base Shelf Prospectus Toronto, Canada; Glil Yam, Israel
IMC Announces Filing of Preliminary Short Form Base Shelf Prospectus Toronto, Canada; Glil Yam, Israel - March 12, 2021 - IM Cannabis Corp. (the "Company" or "IMC") (CSE:IMCC, NASDAQ:IMCC), a multi-country operator ("MCO") in the medical cannabis sector with operations in Israel
Read more →-IMCC
Mar 9, 2021Filed by newsfilecorp.com SUPPLEMENTAL WARRANT INDENTURE THIS SECOND SUPPLEMENTAL WARRANT INDENTURE dated as of the 12th day of February, 2021, to the Warrant Indenture made as of
SUPPLEMENTAL WARRANT INDENTURE THIS SECOND SUPPLEMENTAL WARRANT INDENTURE dated as of the 12th day of February, 2021, to the Warrant Indenture made as of August 30, 2019 and supplemented on November 14, 2019, IM CANNABIS CORP. (formerly Navasota Resources Inc.), a corporation e
Read more →Competitive Position
How IMCC ranks across every disease it competes inCompetitive Position is a premium feature
See how IMCC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial